Xiaojuan Li1,2,3, Stephen R Cole1, Abhijit V Kshirsagar2, Jason P Fine4, Til Stürmer1, M Alan Brookhart1. 1. Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 2. University of North Carolina Kidney Center, Division of Nephrology and Hypertension, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 3. Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts 4. Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Abstract
BACKGROUND AND OBJECTIVES: Intravenous iron therapy for chronic anemia management is largely driven by dosing protocols that differ in intensity with respect to dosing approach (i.e., dose, frequency, and duration). Little is known about the safety of these protocols. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Using clinical data from a large United States dialysis provider linked to health care utilization data from Medicare, we constructed a cohort of patients with ESKD aged ≥65 years who initiated and continued center-based hemodialysis for ≥90 days between 2009 and 2012, and initiated at least one of the five common intravenous iron administration strategies; ranked by intensity (the amount of iron given at moderate-to-high iron indices), the order of strategies was 3 (least intensive), 2 (less intensive), 1 (reference), 4 (more intensive), and 5 (most intensive). We estimated the effect of continuous exposure to these strategies on cumulative risks of mortality and infection-related events with dynamic Cox marginal structural models. RESULTS: Of 13,249 eligible patients, 1320 (10%) died and 1627 (12%) had one or more infection-related events during the 4-month follow-up. The most and least commonly initiated strategy was strategy 2 and 5, respectively. Compared with the reference strategy 1, more intensive strategies (4 and 5) demonstrated a higher risk of all-cause mortality (e.g., most intensive strategy 5: 60-day risk difference: 1.3%; 95% confidence interval [95% CI], 0.8% to 2.1%; 120-day risk difference: 3.1%; 95% CI, 1.0% to 5.6%). Similarly, higher risks were observed for infection-related morbidity and mortality among more intensive strategies (e.g., strategy 5: 60-day risk difference: 1.8%; 95% CI, 1.2% to 2.6%; 120-day risk difference: 4.3%; 95% CI, 2.2% to 6.8%). Less intensive strategies (2 and 3) demonstrated lower risks of all-cause mortality and infection-related events. CONCLUSIONS: Among dialysis patients surviving 90 days, subsequent intravenous iron administration strategies promoting more intensive iron treatment at moderate-to-high iron indices levels are associated with higher risks of mortality and infection-related events.
BACKGROUND AND OBJECTIVES: Intravenous iron therapy for chronic anemia management is largely driven by dosing protocols that differ in intensity with respect to dosing approach (i.e., dose, frequency, and duration). Little is known about the safety of these protocols. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Using clinical data from a large United States dialysis provider linked to health care utilization data from Medicare, we constructed a cohort of patients with ESKD aged ≥65 years who initiated and continued center-based hemodialysis for ≥90 days between 2009 and 2012, and initiated at least one of the five common intravenous iron administration strategies; ranked by intensity (the amount of iron given at moderate-to-high iron indices), the order of strategies was 3 (least intensive), 2 (less intensive), 1 (reference), 4 (more intensive), and 5 (most intensive). We estimated the effect of continuous exposure to these strategies on cumulative risks of mortality and infection-related events with dynamic Cox marginal structural models. RESULTS: Of 13,249 eligible patients, 1320 (10%) died and 1627 (12%) had one or more infection-related events during the 4-month follow-up. The most and least commonly initiated strategy was strategy 2 and 5, respectively. Compared with the reference strategy 1, more intensive strategies (4 and 5) demonstrated a higher risk of all-cause mortality (e.g., most intensive strategy 5: 60-day risk difference: 1.3%; 95% confidence interval [95% CI], 0.8% to 2.1%; 120-day risk difference: 3.1%; 95% CI, 1.0% to 5.6%). Similarly, higher risks were observed for infection-related morbidity and mortality among more intensive strategies (e.g., strategy 5: 60-day risk difference: 1.8%; 95% CI, 1.2% to 2.6%; 120-day risk difference: 4.3%; 95% CI, 2.2% to 6.8%). Less intensive strategies (2 and 3) demonstrated lower risks of all-cause mortality and infection-related events. CONCLUSIONS: Among dialysis patients surviving 90 days, subsequent intravenous iron administration strategies promoting more intensive iron treatment at moderate-to-high iron indices levels are associated with higher risks of mortality and infection-related events.
Authors: George R Bailie; Maria Larkina; David A Goodkin; Yun Li; Ronald L Pisoni; Brian Bieber; Nancy Mason; Lin Tong; Francesco Locatelli; Mark R Marshall; Masaaki Inaba; Bruce M Robinson Journal: Kidney Int Date: 2014-07-30 Impact factor: 10.612
Authors: Wieneke M Michels; Bernard G Jaar; Patti L Ephraim; Yang Liu; Dana C Miskulin; Navdeep Tangri; Deidra C Crews; Julia J Scialla; Tariq Shafi; Stephen M Sozio; Karen Bandeen-Roche; Courtney J Cook; Klemens B Meyer; L Ebony Boulware Journal: Nephrol Dial Transplant Date: 2017-01-01 Impact factor: 5.992
Authors: Mahesh Krishnan; Eric D Weinhandl; Scott Jackson; David T Gilbertson; Eduardo Lacson Journal: Am J Kidney Dis Date: 2015-05-23 Impact factor: 8.860
Authors: Dana C Miskulin; Navdeep Tangri; Karen Bandeen-Roche; Jing Zhou; Aidan McDermott; Klemens B Meyer; Patti L Ephraim; Wieneke M Michels; Bernard G Jaar; Deidra C Crews; Julia J Scialla; Stephen M Sozio; Tariq Shafi; Albert W Wu; Courtney Cook; L Ebony Boulware Journal: Clin J Am Soc Nephrol Date: 2014-10-15 Impact factor: 8.237
Authors: Alan S Kliger; Robert N Foley; David S Goldfarb; Stuart L Goldstein; Kirsten Johansen; Ajay Singh; Lynda Szczech Journal: Am J Kidney Dis Date: 2013-07-25 Impact factor: 8.860
Authors: Iain C Macdougall; Sunil Bhandari; Claire White; Stefan D Anker; Kenneth Farrington; Philip A Kalra; Patrick B Mark; John J V McMurray; Chante Reid; Michele Robertson; Charles R V Tomson; David C Wheeler; Christopher G Winearls; Ian Ford Journal: J Am Soc Nephrol Date: 2020-04-06 Impact factor: 10.121
Authors: Angelo Karaboyas; Hal Morgenstern; Nancy L Fleischer; Douglas E Schaubel; Bruce M Robinson Journal: Clin Epidemiol Date: 2020-11-11 Impact factor: 4.790
Authors: Lucia Del Vecchio; Robert Ekart; Charles J Ferro; Jolanta Malyszko; Patrick B Mark; Alberto Ortiz; Pantelis Sarafidis; Jose M Valdivielso; Francesca Mallamaci Journal: Clin Kidney J Date: 2020-11-26
Authors: Tomas Ganz; George R Aronoff; Carlo A J M Gaillard; Lawrence T Goodnough; Iain C Macdougall; Gert Mayer; Graça Porto; Wolfgang C Winkelmayer; Jay B Wish Journal: Kidney Med Date: 2020-03-27